Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCULK7)

• Drug Name: Lazabemide Drug Info
• Synonyms: 103878-84-8; Ro-19-6327; N-(2-Aminoethyl)-5-chloropicolinamide; CCRIS 7301; UNII-420HD787N9; N-(2-aminoethyl)-5-chloropyridine-2-carboxamide; Ro 19-6327 hydrate; CHEMBL279390; Ro 19-6327/000; 420HD787N9; C8H10ClN3O; 2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-; N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate; N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide;N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide; NCGC00167737-01; Lazabemide [USAN:INN]; Lazabemide [USAN:INN:BAN]; Lazabemine; Pakio; Tempium; Ro-41-3776; Ro-19-6327/000; LAZEBEMIDE

Indication

Disease Entry	ICD 11	Status	REF
Skin imperfections	EK71	Patented	[1]
Cognitive impairment	6D71	Discontinued in Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 71307
  CAS Number: CAS 103878-84-8
  TTD Drug ID: DMCULK7

Molecule-Related Drug Atlas

Drug(s) Targeting Monoamine oxidase (MAO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[1]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[1]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[1]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[1]
Methylene blue	DMJAPE7	Acquired methemoglobinemia	3A93	Approved	[5]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[1]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[1]
Ergoloid mesylate	DMORPBA	Alzheimer disease	8A20	Approved	[6]
Cyclopropylamine derivative 11	DMMJ0YN	N. A.	N. A.	Patented	[7]
PMID27019002-Compound-20a	DMRX748	N. A.	N. A.	Patented	[7]

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[8]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[9]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[10]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[11]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[12]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[13]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[14]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[15]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[16]
Budipine	DMODHQI	Migraine	8A80	Approved	[17]

Drug(s) Affected By Amine oxidase B (MAOB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[18]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[19]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[21]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[22]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[23]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[24]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[25]
BENZYL BENZOATE	DMDPYI5	Infestations of lice and scabies	1G00.Z	Approved	[26]
Linezolid	DMGFPU2	Bacteremia	1A73	Approved	[27]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase (MAO)	TT32XQJ	NOUNIPROTAC	Inhibitor	[1]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Amine oxidase B (MAOB)	OTTDFM1O	AOFB_HUMAN	Gene/Protein Processing	[4]

References

• [1] Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6640).
• [3] The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37.
• [4] Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease. Clin Neuropharmacol. 1999 Nov-Dec;22(6):340-6.
• [5] Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
• [8] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [9] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [10] Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [12] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [13] Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
• [14] Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
• [15] Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [17] Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
• [18] Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine. Toxicol Lett. 2016 Jan 22;243:48-55.
• [19] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [20] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [21] Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. ACS Med Chem Lett. 2011 Oct 15;3(1):39-42.
• [22] Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors. J Med Chem. 2011 Jul 28;54(14):5165-73.
• [23] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [24] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [25] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [26] Combining initro and in silico approaches to evaluate the multifunctional profile of rosmarinic acid from Blechnum brasiliense on targets related to neurodegeneration. Chem Biol Interact. 2016 Jul 25;254:135-45.
• [27] Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chem Res Toxicol. 2021 May 17;34(5):1348-1354. doi: 10.1021/acs.chemrestox.0c00524. Epub 2021 Apr 29.